Treatment-resistant depression is not a single entity. Among patients who meet criteria for TRD (failure of two or more appropriate antidepressant trials at adequate dose and duration), substantial heterogeneity exists in underlying biology. The inflamed TRD subtype — patients whose refractory depression is driven significantly by chronic systemic inflammation — represents a clinically identifiable and increasingly treatable population. Recognizing this subtype changes which interventions are most likely to help and which standard moves are likely to continue producing partial response.
The clinical features that suggest inflamed depression include: atypical features (fatigue dominant, hypersomnia rather than insomnia, increased appetite and weight gain rather than decreased, mood reactivity, leaden paralysis); anhedonia disproportionate to other symptoms; severe fatigue that does not improve with classic antidepressant treatment; comorbid medical conditions associated with chronic inflammation (autoimmune disease, metabolic syndrome, chronic infection, periodontal disease, sleep apnea); elevated inflammatory markers (hs-CRP over 3 mg/L, elevated IL-6); failure to respond to multiple monoaminergic agents at adequate dose and duration. No single feature is diagnostic; the cluster identifies the patient population.
The treatment approach is multi-modal and inflammation-targeted. Standard antidepressants remain part of the regimen but are augmented rather than replaced. Lifestyle interventions become urgent: aggressive exercise prescription, sleep optimization with apnea workup, dietary anti-inflammatory pattern, weight management, alcohol reduction. Specific anti-inflammatory pharmacological additions: omega-3 fatty acids (EPA-predominant, 1–2g daily — RCT evidence specifically in inflamed depression); lithium augmentation (anti-inflammatory effects beyond mood stabilization); selective serotonin agents may be preferred over noradrenergic in inflamed phenotype; consideration of NSAID augmentation in severely refractory cases with persistent CRP elevation.
The role of celecoxib and other anti-inflammatory medications as antidepressant augmentation has accumulated meaningful evidence. Several randomized trials have shown that adding celecoxib to standard antidepressant treatment produces faster and larger response in patients with elevated inflammatory markers. The effect is most evident in inflamed depression specifically; uniform NSAID augmentation across all TRD does not produce the same signal. The clinical caveat is that NSAIDs have their own risk profile (cardiovascular, GI, renal) that must be weighed; the augmentation is appropriate for selected patients, not a universal recommendation.
Newer and emerging anti-inflammatory strategies include: Minocycline (the antibiotic with neuroinflammation-modulating effects, accumulating evidence in mood disorders); Anti-cytokine therapy (TNF-alpha inhibitors in research contexts, showing antidepressant effects in patients with elevated inflammatory markers, though the cost and access remain barriers); Vagal nerve stimulation (FDA-approved for TRD; some of its effects may be anti-inflammatory through cholinergic anti-inflammatory pathway); Ketamine (its rapid antidepressant effect may involve anti-inflammatory mechanisms; particularly effective in some inflamed phenotypes). The pharmacological landscape is expanding in ways that map specifically onto the inflamed subtype.
The clinical implication is to characterize inflammation early in the TRD workup. Patients arriving at TRD designation have typically tried multiple monoaminergic agents; continuing to cycle through more of the same class without addressing inflammation is unlikely to produce different results. The longevity-psychiatry move is to expand the workup to include inflammatory characterization at the point where the second antidepressant trial fails, not after the fifth or sixth. Early identification of the inflamed subtype redirects treatment toward strategies that have a better chance of working.